LinkedInFacebookTwitterRssEmail
(832) 968-8698|sales@avancebio.com

Customer News

20 05, 2026

GUIDE-seq and NGS-based off-target analysis support genome editing safety assessment for engineered Treg therapy

2026-05-20T20:33:05+00:00

GentiBio recently presented genome editing safety data during the “On- and Off-Target Method Development” session st the 2026 ASGCT Meeting, highlighting the extensive off-target characterization strategy used to support development of GNTI-122, an engineered regulatory T cell (Treg) therapy for type 1 diabetes (T1D). The presentation is particularly timely given the recent FDA [...]

GUIDE-seq and NGS-based off-target analysis support genome editing safety assessment for engineered Treg therapy2026-05-20T20:33:05+00:00
6 05, 2025

Verve Therapeutics Reports Promising Results for PCSK9 Gene Editing in HeFH

2026-04-22T18:04:54+00:00

Verve Therapeutics’ VERVE-102 shows early success in lowering LDL cholesterol by 55% with a single dose, offering a potential one-time gene editing treatment for familial hypercholesterolemia...

Verve Therapeutics Reports Promising Results for PCSK9 Gene Editing in HeFH2026-04-22T18:04:54+00:00
11 03, 2025

Breakthrough in Genetic Medicine: Beam Therapeutics Shows Potential with BEAM-302 for Alpha-1 Antitrypsin Deficiency

2026-04-22T18:03:53+00:00

Beam Therapeutics announces groundbreaking results from its Phase 1/2 trial of BEAM-302, demonstrating the first-ever clinical genetic correction for Alpha-1 Antitrypsin Deficiency (AATD), offering hope for a potential one-time cure for this genetic disorder...

Breakthrough in Genetic Medicine: Beam Therapeutics Shows Potential with BEAM-302 for Alpha-1 Antitrypsin Deficiency2026-04-22T18:03:53+00:00
27 06, 2023

A historic first for gene therapy

2026-04-22T18:04:46+00:00

Sarepta Therapeutics announces FDA approval of ELEVIDYS, the first gene therapy to treat Duchenne Muscular Dystrophy. ELEVIDYS addresses the root genetic cause of Duchenne – mutations in the dystrophin gene that result in the lack of dystrophin protein – by delivering a gene that codes for a shortened form of dystrophin to muscle cells known as ELEVIDYS micro-dystrophin...

A historic first for gene therapy2026-04-22T18:04:46+00:00
13 06, 2023

2seventy bio presents broad range of new data highlighting novel approaches across its cell therapies portfolio

2026-04-22T18:03:59+00:00

2seventy bio announced new data featuring novel approaches combining the company’s platform CAR T cell and T cell receptor technology and unique cell therapy engineering capabilities to potentially enhance treatment potency in a range of cancers...

2seventy bio presents broad range of new data highlighting novel approaches across its cell therapies portfolio2026-04-22T18:03:59+00:00
16 05, 2023

New preclinical data from Sana Biotechnology highlights the potential of CAR T cell therapy

2026-04-22T18:04:32+00:00

Preclinical data demonstrates that hypoimmune-modified allogeneic iPSCs evade immune response and rejection without immunosuppression in a non-human primate model and long-term survival and immune evasion was at least equivalent to the survival of autologous iPSCs...

New preclinical data from Sana Biotechnology highlights the potential of CAR T cell therapy2026-04-22T18:04:32+00:00
26 10, 2022

Kyverna Therapeutics Submits IND for Novel CAR T-Cell Therapy to Treat Lupus Nephritis

2026-04-22T18:04:18+00:00

Company files its first Investigational New Drug application for its lead program KYV-101, a novel fully human CD19 CAR T-cell therapy, for the treatment of lupus nephritis. Kyverna’s therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate...

Kyverna Therapeutics Submits IND for Novel CAR T-Cell Therapy to Treat Lupus Nephritis2026-04-22T18:04:18+00:00
13 09, 2022

Kyverna Therapeutics’ $85 million series B financing reflects significant investor confidence in the science behind cell therapies

2026-04-22T18:04:37+00:00

Kyverna Therapeutics, a cell therapy company engineering a new class of therapies for serious autoimmune diseases, today announced it has closed an oversubscribed $85 million Series B financing round led by Northpond Ventures. Additional investors included the company’s founding investors Westlake Village BioPartners (“Westlake”), Vida Ventures, and Gilead Sciences (“Gilead”), with new investors RTW [...]

Kyverna Therapeutics’ $85 million series B financing reflects significant investor confidence in the science behind cell therapies2026-04-22T18:04:37+00:00

ABOUT US

Avance Biosciences is a leading Contract Research Organization (CRO) and Contract Testing Organization (CTO) providing CGMP and GLP-compliant analytical and bioanalytical services to support drug development. From early discovery through clinical development and commercialization, we provide CGMP and GLP-compliant services tailored to your therapeutic modality and regulatory needs.

NEWSLETTER SIGNUP

21 CFR Part 11 Compliant
FDA Inspected
CLIA Registered

CONTACT US

  • 5500 NW Central Dr, Houston TX 77092

RECENT NEWS

Go to Top